Table 1.

Outcome measures for the trial

Endpoint	Name	Population	Brief description
Primary	Laboratory-confirmed Aedes-borne disease	2–15-year-olds at enrollment	Laboratory-confirmed (virologically [RT-PCR testing of acute samples] or serologically [IgM and IgG ELISA testing of paired acute and convalescent samples]) symptomatic DENV, CHIKV, or ZIKV
Secondary	Laboratory-confirmed Aedes-borne infection	2–15-year-olds at enrollment	Laboratory-confirmed (serologically, [IgG ELISA and neutralization testing of annual surveillance samples]) DENV, CHIKV, or ZIKV infection. A FRNT50 for one DENV serotype ≥ 4-fold the FRNT50 to the other 3 serotypes is considered DENV mono-immune seroconversion
Secondary	Aedes aegypti infection with Aedes-borne viruses	Female Ae. aegypti collected in central 3 × 3 blocks of each cluster	Ae. aegypti mosquito infection rates with DENV, CHIKV, and ZIKV (assessed by RT-PCR) from 10% of households
Secondary	Aedes aegypti infestation	Ae. aegypti collected in central 3 × 3 blocks of each cluster	Ae. aegypti indoor entomological indices (adult presence and abundance, female presence and abundance, blood-fed female and abundance) from 10% of households
Secondary	Community acceptability of TIRS	Head of household in clusters receiving TIRS	Households receiving the intervention will be asked about their response and issues with TIRS. Conducted on same houses where entomology occurs.
Secondary	Community impact of TIRS	All ages	Number of symptomatic ABV cases reported to the passive surveillance system, including children and adults, distributed in treatment and control clusters
Secondary	Safety profile	All houses in 5 × 5 block treatment clusters	Percentage of households receiving the intervention that had evidence of a reaction to the insecticide (assessed and confirmed by study doctors). All sprayed households are eligible.